Get the Stockscreener App
19.18
2.59%
-0.51
After Hours:
19.26
0.08
+0.42%
Denali Therapeutics Inc stock is traded at $19.18, with a volume of 1.40M.
It is down -2.59% in the last 24 hours and up +6.85% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$19.69
Open:
$19.81
24h Volume:
1.40M
Relative Volume:
0.85
Market Cap:
$3.00B
Revenue:
$340.81M
Net Income/Loss:
$-419.65M
P/E Ratio:
-6.7298
EPS:
-2.85
Net Cash Flow:
$-402.10M
1W Performance:
-4.20%
1M Performance:
+6.85%
6M Performance:
+45.08%
1Y Performance:
-7.88%
1-Day Range:
$18.75
$20.21
1-Week Range:
$18.66
$21.31
52-Week Range:
$10.57
$23.77
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8547
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
19.18 | 3.07B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Apr-10-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-07-25 | Resumed | Morgan Stanley | Overweight |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Ideas Watch: Is Denali Therapeutics Inc. a turnaround storyEarnings Growth Summary & Smart Money Movement Tracker - baoquankhu1.vn
Principal Financial Group Inc. Purchases 198,207 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) Gets a Buy from Wedbush - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Haemonetics (HAE) and Denali Therapeutics (DNLI) - The Globe and Mail
Published on: 2026-02-08 06:47:50 - baoquankhu1.vn
Denali Therapeutics (NASDAQ:DNLI) Earns Buy Rating from BTIG Research - MarketBeat
Earnings Recap: Is Denali Therapeutics Inc forming a bullish divergenceBull Run & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Denali Therapeutics Showcases ETV Data at WORLD: TIVI PDUFA Near, DNL126 Hits 80% CSF Drop - MarketBeat
DNLI: Sustained biomarker normalization and clinical gains achieved in Hunter syndrome and MPS IIIA - TradingView
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™ - The Manila Times
Denali Therapeutics Reports Promising Clinical Trial Data for Tividenofusp Alfa and Other Enzyme Replacement Therapies in Lysosomal Storage Disorders - Quiver Quantitative
Trial data track Denali enzyme drugs for rare brain and muscle diseases - Stock Titan
A Look At Denali Therapeutics (DNLI) Valuation As New ETV Rare Disease Data Presentations Approach - Yahoo Finance
How Denali’s Brain-Targeted ETV Data and FDA Review Will Impact Denali Therapeutics (DNLI) Investors - Yahoo Finance
Denali Therapeutics Inc. (DNLI): Investor Outlook Reveals 44.49% Potential Upside In Neurodegenerative Drug Development - DirectorsTalk Interviews
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView
Is Denali Therapeutics Inc stock suitable for long term investingJuly 2025 Sentiment & Weekly High Conviction Ideas - baoquankhu1.vn
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium - The Globe and Mail
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™ - The Manila Times
Denali to outline enzyme delivery to the brain in 2026 WORLDSymposium webcast - stocktitan.net
AlphaQuest LLC Raises Stake in Denali Therapeutics Inc. $DNLI - MarketBeat
(DNLI) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Assessing Denali Therapeutics (DNLI) Valuation As WORLDSymposium Data And FDA Priority Review Draw Closer - Sahm
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™ - The Manila Times
Denali to present clinical data on rare disease therapies at WORLDSymposium By Investing.com - Investing.com South Africa
Denali to present clinical data on rare disease therapies at WORLDSymposium - Investing.com Nigeria
Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials - TechStock²
New enzyme studies for Hunter, Sanfilippo and Pompe at 2026 WORLDSymposium - stocktitan.net
Energy Moves: Is Denali Therapeutics Inc part of any ETFJuly 2025 Selloffs & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Denali Therapeutics (DNLI) Gets a Buy from Bank of America Securities - The Globe and Mail
REGENXBIO Delay Could Put Denali in Pole Position for Hunter Syndrome Approval - BioSpace
Stop Loss: How does Aclarion Inc Equity Warrant correlate with NasdaqJuly 2025 Rallies & Community Trade Idea Sharing Platform - baoquankhu1.vn
Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring a 59% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Short Covering: What are the future prospects of Lotterycom IncInsider Selling & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Denali Therapeutics Inc. $DNLI Shares Sold by Baillie Gifford & Co. - MarketBeat
Certain Stock Options of Denali Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 24-JAN-2026. - marketscreener.com
Denali Therapeutics (NASDAQ:DNLI) Shares Up 11.3%Here's Why - MarketBeat
Shorts Report: What are analysts price targets for Denali Therapeutics IncExit Point & AI Forecast for Swing Trade Picks - baoquankhu1.vn
3 Biotech Stocks That Could Double In 2026 - AOL.com
Stock Market Recap: What are analysts price targets for Denali Therapeutics IncJuly 2025 Rallies & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Liquidity Mapping Around (DNLI) Price Events - Stock Traders Daily
Aug Big Picture: Can Denali Therapeutics Inc withstand a market correctionRate Hike & Daily Volume Surge Signals - baoquankhu1.vn
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Buy" by Brokerages - MarketBeat
Aug Breakouts: Whats the outlook for Denali Therapeutics Incs sectorPrice Action & Community Trade Idea Sharing Platform - baoquankhu1.vn
Aug Chart Watch: Whats the outlook for Denali Therapeutics Incs sectorAnalyst Downgrade & Long Hold Capital Preservation Plans - baoquankhu1.vn
An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 40% Undervalued - 富途牛牛
Campbell & CO Investment Adviser LLC Purchases 74,066 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Aug Patterns: Can Denali Therapeutics Inc withstand a market correctionMarket Performance Recap & Weekly High Conviction Trade Ideas - baoquankhu1.vn
FOMO Trade: What makes FTRE stock attractive todayInflation Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Denali Therapeutics stock maintains Buy rating at Goldman Sachs on pipeline progress - Investing.com
Earnings Recap: Is BranchOut Food Inc a strong growth stockAnalyst Upgrade & AI Powered Market Trend Analysis - baoquankhu1.vn
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):